"Glucagon-Like Peptide 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A peptide of 36 or 37 amino acids that is derived from PROGLUCAGON and mainly produced by the INTESTINAL L CELLS. GLP-1(1-37 or 1-36) is further N-terminally truncated resulting in GLP-1(7-37) or GLP-1-(7-36) which can be amidated. These GLP-1 peptides are known to enhance glucose-dependent INSULIN release, suppress GLUCAGON release and gastric emptying, lower BLOOD GLUCOSE, and reduce food intake.
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide 1".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide 1".
This graph shows the total number of publications written about "Glucagon-Like Peptide 1" by people in Harvard Catalyst Profiles by year, and whether "Glucagon-Like Peptide 1" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 5 | 5 |
| 1999 | 0 | 6 | 6 |
| 2000 | 0 | 4 | 4 |
| 2001 | 0 | 6 | 6 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 4 | 4 |
| 2004 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 1 | 3 | 4 |
| 2008 | 5 | 1 | 6 |
| 2009 | 3 | 3 | 6 |
| 2010 | 4 | 6 | 10 |
| 2011 | 9 | 7 | 16 |
| 2012 | 6 | 2 | 8 |
| 2013 | 9 | 4 | 13 |
| 2014 | 5 | 7 | 12 |
| 2015 | 4 | 4 | 8 |
| 2016 | 9 | 4 | 13 |
| 2017 | 5 | 4 | 9 |
| 2018 | 1 | 4 | 5 |
| 2019 | 3 | 7 | 10 |
| 2020 | 3 | 7 | 10 |
| 2021 | 0 | 6 | 6 |
| 2022 | 0 | 18 | 18 |
| 2023 | 3 | 13 | 16 |
| 2024 | 0 | 5 | 5 |
Below are the most recent publications written about "Glucagon-Like Peptide 1" by people in Profiles.
-
An Intricate Network Involving the Argonaute ALG-1 Modulates Organismal Resistance to Oxidative Stress. Nat Commun. 2024 Apr 09; 15(1):3070.
-
Age-Related Usage of GLP-1 Agonists in Obese Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2024 Apr 09; 83(14):1348-1350.
-
Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2024 Apr 01; 47(4):610-619.
-
Risk of Anaphylaxis Among New Users of GLP-1 Receptor Agonists: A Cohort Study. Diabetes Care. 2024 Apr 01; 47(4):712-719.
-
Delivery Device Patents on GLP-1 Receptor Agonists. JAMA. 2024 03 05; 331(9):794-796.
-
Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists. ESC Heart Fail. 2024 Apr; 11(2):649-661.
-
Newer pharmacological interventions directed at gut hormones for obesity. Br J Pharmacol. 2024 Apr; 181(8):1153-1164.
-
RET Signaling Persists in the Adult Intestine and Stimulates Motility by Limiting PYY Release From Enteroendocrine Cells. Gastroenterology. 2024 Mar; 166(3):437-449.
-
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024 02 06; 149(6):450-462.
-
Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study. Diabet Med. 2024 Apr; 41(4):e15248.